FDA actions in India severely cuts drug exports: Boehringer Ingelheim has big biosimilar plans;

> Actions by the FDA against Indian drugmakers cut that country's pharmaceutical export growth to about 5% this year. Story

> BASF said it will add to its amines capacity with a new plant in Germany. Release

> Abbott ($ABT) earnings were hurt by last year's recall of baby formula in China tied to a supplier's manufacturing problems. Story

> India's Glenmark is recalling 2,900 bottles of rantidine tablets in the U.S. Report

And Finally... Boehringer Ingelheim says it will manufacture biosimilar versions of Humira, Avastin and MabThera/Rituxan as part of its plans on that front. Story